Vol 2, Issue 1

Table of Contents

Original Articles

by Levent Akyüz, Andreas Wilhelm, Florian Butke, Park Su-Jin, Anja Kuckuck, Hans-Dieter Volk, Gerald Grütz
1490 Views, 1441 PDF Downloads
The parallel analysis of multiple factors, such as cytokines, from small sample size is an interesting approach for assessment of in vivo activation signatures and functionality after ex vivo stimulation. One interesting application is for therapy monitoring, such as safety data, pharmacodynamics, evidences for mode-of-action and side effects, particularly useful for accompanying early phase clinical trials. There are different platforms for Multiplex analysis of ligands available. We compared in this study the performance of three different platforms (Luminex Bio-Plex® 200, MesoScale Discovery®, Ella®) which use different ways of achieving parallel measurements of biomarkers from small liquid sample size. We show examples of in house assessment of intra- and inter-assay variations, determination of range and recovery for classical immunological serum markers and discuss advantages and disadvantages for these three platforms in relation to the question addressed.

Review Articles

by Lilla Landeck, Adriana Amasuno, Ignasi Pau-Charles, Khusru Asadullah
479 Views, 281 PDF Downloads

A mixture of fumaric acid esters (FAEs) is approved for the oral therapy of psoriasis. However, for a long time the active ingredient of this mixture was unknown. We reviewed the in vitro data available for the different FAEs present in the multi compound drug and elaborate how they may contribute to possible clinical effects. Although helpful overall, many in vitro data must be viewed critically because the concentrations used in the experiments exceed the plasma levels reached in patients. The data suggest that dimethylfumarate (DMF) is the most active compound, mediating the major therapeutic effect after metabolization into MMF via an according receptor expressed on target cells. Identifying the active pharmaceutical ingredient within a mixture of compounds helps to subsequently eliminate unnecessary, potentially harmful compounds. This provides a promising example for an alternative precision medicine approach in clinical practice.

Perspective Articles

by Basil Harris Chaballout, Ryan Jeffry Shaw, Karin Reuter-Rice
671 Views, 894 PDF Downloads
Substitutable Medical Apps Reusable Technologies (SMART®) on Fast Healthcare Interoperability Resources (FHIR) is an open, standards platform that allows third parties to build health applications that interact with EHR systems. This can allow for aggregation of unique data ranging from genomics to lifestyle, thereby promoting the emerging precision medicine approach. It is also the first to provide a way to successfully incorporate interoperability in EHRs and precision medicine implementation.